This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Fulcrum Therapeutics' Phase 1b PIONEER Trial of Pociredir 20mg in Sickle Cell Disease.
Ticker(s): FULCWho's the expert?
Institution: Rutgers Medical School
- Clinical Section Chief, Pediatric Hematology/Oncology and Director, Comprehensive Sickle Cell Center at Rutgers Cancer Institute of New Jersey; Vice Chair, IRB at Rutgers Biomedical and Health Sciences; and Vice Chair, NCI Pediatric Central IRB.
- Currently manages 450 patients with sickle cell disease and sees 20/year with cisplatin induced hearing loss.
- Research focuses on Hodgkin Disease, Pediatric oncology/ hematology, and Sickle cell disease.
Interview GoalThis conversation will focus on the treatment landscape and potential use of Pociredir 20mg in patients with sickle cell disease.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Jan 14, 2026
- Call Time
- 09:55 AM EST
Wall Street Time
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
